New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2013
06:45 EDTAMRNAmarin submits sNDA for Vascepa
Amarin Corporation announced that it has submitted a Supplemental New Drug Application, or sNDA, with the FDA seeking approval for the marketing and sale of Vascepa capsules for use as an adjunct to diet in the treatment of adult patients with high triglycerides with mixed dyslipidemia. Amarin expects to hear within 74 days from the FDA whether the sNDA submission has been accepted for review.
News For AMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
08:00 EDTAMRNAmarin Q1 Vascepa sales estimate lowered at SunTrust
Subscribe for More Information
March 31, 2015
11:36 EDTAMRNAmarin management to meet with SunTrust
Subscribe for More Information
March 20, 2015
05:51 EDTAMRNStocks with implied volatility movement; AMRN EWG
Stocks with implied volatility movement; Amarin (AMRN) 140, iShares MSCI Germany (EWG) 20 according to iVolatility.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use